# Daiichi Sankyo, Inc. – FDA Inspection, Jan 8, 2019

Source: https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-inc/a601fba2-871e-472e-9dd9-25db2a50d807
Source feed: FDA_Inspections

> FDA inspection 1076061 of Daiichi Sankyo, Inc., January 08, 2019. Classification: Voluntary Action Indicated (VAI). 1 citation under 21 CFR part 312. Form 483 issued. 10 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1076061
- Company Name: Daiichi Sankyo, Inc.
- Inspection Date: 2019-01-08
- Classification: Voluntary Action Indicated (VAI)
- Classification Code: VAI
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 1

## Related Documents

- FDA Inspection 1318108 - 2026-05-04
- [FDA Inspection 1277224 - 2025-08-01](https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-inc/63bf611c-4ad7-4991-8f19-7cdec7f9e84b)
- FDA Inspection 1192012 - 2022-11-30
- FDA Inspection 1176597 - 2022-07-15
- FDA Inspection 1168866 - 2022-04-08

## Related Officers

- [FDA Associated Person](https://www.keypedia.com/people/peter-r-lenahan/c695dac2-5447-434b-801e-f95e6acf05f1)

Company: https://www.keypedia.com/companies/daiichi-sankyo-inc/fd789c74-6b2b-43fb-800d-326eceeb1aea

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c